Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice

Anneliese Ashhurst

The University of Sydney

Matt Johansen

University of Technology Sydney

Joshua Maxwell

University of Sydney

Caroline Ashley

University of Sydney

Anupriya Aggarwal

UNSW Sydney

Rezwan Siddiquee

The University of Sydney

Stefan Miemczyk

University of Technology Sydney

Duc Nguyen

University of Technology Sydney

Joel Mackay

University of Sydney <https://orcid.org/0000-0001-7508-8033>

Claudio Counoupas

University of Sydney

Scott Byrne

The Westmead Institute for Medical Research <https://orcid.org/0000-0003-3029-1710>

Stuart Turville

Kirby Institute UNSW Sydney <https://orcid.org/0000-0003-1918-5343>

Megan Steain

The University of Sydney

James Triccas

University of Sydney <https://orcid.org/0000-0003-3730-2339>

Philip Hansbro

University of Technology Sydney <https://orcid.org/0000-0002-4741-3035>

Richard Payne

University of Sydney <https://orcid.org/0000-0002-3618-9226>

Warwick Britton (✉ w.britton@centenary.org.au)

Centenary Institute, The University of Sydney <https://orcid.org/0000-0001-6721-9646>

Article

Keywords:

Posted Date: January 5th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1179181/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Nature Communications on November 15th, 2022. See the published version at <https://doi.org/10.1038/s41467-022-34297-3>.

Abstract

Current vaccines against SARS-CoV-2 substantially reduce mortality, but protection against infection is less effective. Enhancing immunity in the respiratory tract, *via* mucosal vaccination, may provide protection against infection and minimise viral spread. We tested a novel subunit vaccine in mice, consisting of SARS-CoV-2 Spike protein with a TLR2-stimulating adjuvant, delivered to mice parenterally or mucosally. Both routes of vaccination induced substantial neutralising antibody (nAb) titres, however, mucosal vaccination uniquely generated anti-Spike IgA, increased nAb in the serum and airways, and increased lung CD4⁺ T-cell responses. TLR2 is expressed by respiratory epithelia and immune cells. Using TLR2 deficient chimeric mice, we determined that TLR2 expression in either compartment facilitated early innate responses to mucosal vaccination. By contrast, TLR2 on hematopoietic cells was essential for optimal lung-localised, antigen-specific responses. In a K18-hACE2 mice, vaccination provided complete protection against disease and sterilising lung immunity against SARS-CoV-2. These data support mucosal vaccination as a strategy to improve protection in the respiratory tract against SARS-CoV-2 and other respiratory viruses.

Introduction

The emergence of SARS-CoV-2 in late 2019 and the subsequent global COVID-19 pandemic has led to substantial morbidity and mortality with currently over 260 million confirmed cases and 5.2 million deaths reported to the World Health Organisation. The development of vaccines against SARS-CoV-2 has reduced the morbidity and mortality associated with COVID-19 and limited the significant disruption to economies and freedom of movement arising from restrictive, but necessary, public health measures. Most current vaccines, either those approved for clinical use or in development, are delivered by intramuscular injection and these predominantly induce systemic neutralising Immunoglobulin G (IgG) and T-cell responses, but poor mucosal responses¹. Serum IgG transudates into the lungs across the alveolar epithelium to reduce the risk of pulmonary viral infection, but does not prevent infection in the nasal passages and consequent virus shedding, unless neutralising serum IgG is at very high levels². Consequently, while the risk of infection and transmission is reduced by vaccination, breakthrough infections with ongoing spread can still occur³.

Of concern is evidence for the waning of immunity post vaccination or infection^{4,5}, combined with the impact of viral variants of concern (VOCs), including the very recent emergence of the Omicron variant⁶. Currently, resurgence of disease in highly vaccinated populations correlates with time since vaccination and also the emergence of the Delta variant⁷, for which there are suggestions that vaccine effectiveness and control of viral burden are reduced⁸. Additionally, issues surrounding vaccine equity, including affordability, transport of vaccines with complex storage requirements and ease of access, also remain to be fully addressed⁹. A large, partially protected population may create ideal evolutionary conditions to drive emergence of further VOCs with capacity for vaccine immune evasion characteristics or increased pathogenicity, including increased replicative capacity in the upper airway and consequent enhanced

transmission. Thus, there remains a major need to continue investing in vaccine development for SARS-CoV-2.

Enhancing mucosal immunity to provide a barrier against infection may increase protection, and importantly, minimise viral spread¹⁰. Mucosal vaccination has shown exciting potential in pre-clinical studies for multiple respiratory pathogens, generating immunity in the lower respiratory tract to prevent morbidity and mortality. Immunoglobulin A (IgA), which is actively transported across respiratory epithelium as a stabilized dimer¹¹, as well as resident memory B and T cells in the lungs, nasal passages and upper airways, is elicited by intranasal vaccination and can prevent infection and reduce viral shedding¹². In animal models, intranasal vaccination against SARS-CoV-2 can provide barrier protection against infection in both the lung and upper respiratory tract (URT), via the generation of secretory nAbs and memory T-cells in the mucosa^{13–19}. Currently, primarily live-attenuated viruses or viral vector-vaccines have been used for mucosal vaccination, but these may have safety concerns and cannot be used for repeat booster immunization because of anti-vector immunity. Protein vaccines overcome these concerns and provide a cost-effective strategy that is suitable in a wide range of populations, include young, aged²⁰ and immunocompromised groups. However protein vaccines require the inclusion of appropriate immune stimulants to enhance their immunogenicity, and effective and safe mucosal adjuvants are urgently required¹⁰. In addition, direct activation of the respiratory epithelium may increase the delivery of soluble proteins to gain access to antigen presenting cells for immune activation²¹.

Toll-like-receptor 2 (TLR2) is an activating innate immune receptor expressed by both the respiratory epithelium and lung immune cells^{22–24}, and is required for effective host defence against infection²⁵. We and others have recently shown that the TLR2 ligand, Pam₂Cys, is a highly effective mucosal adjuvant for peptide or protein-based vaccines^{26–28 29,30}. Pulmonary immunization with mycobacterial peptides or protein conjugated to Pam₂Cys stimulated protective immunity in the lung against *Mycobacterium tuberculosis* infection^{26–28}. Thus, we examined the pattern of lung and systemic immune responses induced by a novel subunit vaccine, consisting of recombinant trimeric SARS-CoV-2 Spike protein admixed with the TLR2-stimulating adjuvant Pam₂Cys (Pam₂Cys Spike), delivered *via* the mucosal or systemic route. To establish the contribution of TLR2-expression by respiratory epithelia and lung immune cells to the mucosal vaccine response, we developed chimeric mice expressing TLR2 on haemopoietic cells or the epithelium and examined early innate responses and adaptive immunity after mucosal vaccination. Finally, the protective efficacy of the vaccine following mucosal and parenteral delivery was assessed in the K18-hACE2 murine model of SARS-CoV-2 infection³¹.

Results

Pam₂Cys Spike vaccination induces potent lung antibody and CD4⁺ T-cell responses

To compare immune induction by parenteral *versus* mucosal Pam₂Cys Spike vaccination, C57BL/6 mice received three homologous immunizations two weeks apart, either by subcutaneous (s.c) injection or

intranasal (i.n) instillation. Immunogenicity was assessed at one-week post-final vaccination by comparison to unvaccinated mice (Fig. 1a). Vaccination by either route induced potent titres of anti-Spike IgG in serum (10^8) and broncho-alveolar lavage fluid (BALF) (10^7), determined by ELISA, and this was significantly increased in mucosally immunized mice (Fig. 1b). Strikingly, anti-Spike IgA was only detected in the serum or BALF of i.n immunized mice, where it was present at very high titres. The neutralizing potential of these antibodies was assessed in a pseudovirus assay, using infection of HEK293-ACE2 cells with a SARS-CoV-2 Spike-expressing lentivirus (Fig. 1c), as well as against virulent SARS-CoV-2 infection of VeroE6 cells (Fig. 1d). nAb titre was defined as the dilution required to inhibit 50% of infection in either system (EC_{50}). Both s.c or i.n vaccination induced potent nAb titres in serum, however mucosally immunized mice had significantly greater nAb, and only the mucosal immunization route resulted in significantly elevated nAb in the airways.

The generation of local and systemic Spike-specific T-cell responses was assessed by *ex vivo* recall stimulation of lung and spleen leukocytes with Spike protein in the presence of Brefeldin A, intracytoplasmic cytokine staining and quantitation by flow cytometry (gating strategy in Fig. S1). Mucosally immunized mice had a substantial population of Spike-specific $CD4^+$ T-cells locally in the lungs, predominantly secreting IL-17 (Fig. 2a), and a more diverse response systemically in the spleen, with IL-2, IL-17 and TNF-secreting populations significantly increased (Fig. 2b). No significantly increased populations of Spike-specific $CD8^+$ T-cells secreting IFN γ , IL-2 or TNF were detected (Fig. 2c,d). Therefore, Pam₂Cys Spike vaccination was potently immunogenic, inducing powerful anti-SARS-CoV-2 nAb responses in serum, with i.n vaccination providing superior humoral and $CD4^+$ T-cell responses in the lungs and airways.

TLR2 on both respiratory epithelia and lung immune cells contribute to early innate immune responses to mucosal vaccination

TLR2 is expressed by both the respiratory epithelia and lung immune cells^{22–24}, and is required for effective host defence against infection²⁵. We hypothesised that both compartments may contribute to mucosal vaccine responses, providing an explanation for the powerful immunity induced by i.n delivery of Pam₂Cys adjuvanted vaccines. To determine the role played by each compartment, irradiated wild type (WT; BALB/c) and TLR2 deficient (*Tlr2*^{-/-}) mice^{24,25} were reconstituted with either WT or *Tlr2*^{-/-} (KO) bone marrow (BM), to create mice with TLR2 expression on neither compartment (KO/KO BM), immune cells only (KO/WT BM), non-immune cells only (WT/KO BM) or both compartments (WT/WT BM). Mice were rested for 12-weeks to allow hematopoietic reconstitution and replacement of radiation-resistant populations in the lungs and airways. To assess early innate responses to mucosal vaccination, mice were immunized i.n with Pam₂Cys Spike once, then immune populations of the lungs and airways examined by flow cytometry at 24-hours post vaccination (Fig. 3a).

Computational analysis of lung leukocytes was first performed using the Spectre R package³², to perform unbiased clustering of all $CD45^+$ cells. To verify bone marrow replacement, relative expression of TLR2

was examined by Flt-SNE, with expression above background detected only in mice receiving WT BM (Fig. 3b). Clusters with the highest degree of expression were identified, based on phenotypic markers, as alveolar macrophages (SiglecF⁺CD11c^{hi}), neutrophils (Ly6G⁺CD11b^{hi}), and other myeloid subsets including DC (SiglecF⁻CD11c⁺) and monocyte subsets (Ly6C^{hi}CD11b^{hi}, Ly6C^{mid}CD11b^{hi}) (Fig. S2). Manual gating in FlowJo was then performed to identify these subsets, as well as other immune populations of interest (gating strategy in Fig. S3) and TLR2 expression on these cellular populations determined (Fig. S4). A comparison of the proportion of lung immune populations revealed that mice expressing TLR2 either on non-immune or immune compartments, had a similar lung immune profile post vaccination, which was dominated by neutrophil (Ly6G⁺CD11b^{hi}) influx (Fig. 3c). Quantitation of total lung leukocytes and neutrophil count also demonstrated a consistent elevation in mice expressing TLR2 on either compartment (Fig. 3d). Notably, however, innate cells that include classic antigen presenting cells, including dendritic cells (DC; SiglecF⁻CD3⁻B220⁻CD11c⁺MHCII^{hi}), alveolar macrophages (SiglecF⁺CD11c^{hi}) and a monocyte subset (SiglecF⁻CD3⁻B220⁻CD11c⁻CD11b^{hi}Ly6C^{mid}), were significantly elevated in mice that had TLR2 expression on non-immune cells, or both non-immune and immune cells (Fig. 3d). This was despite the expression of TLR2 on these cells only in mice that received WT BM (Fig. S4). Thus, activation of TLR2 on the respiratory epithelia plays a key role in recruiting these innate immune cells to the lungs early after mucosal vaccination.

Examination of immune phenotypes in BALF samples revealed a similar pattern, whereby mice expressing TLR2 on either immune or non-immune cells had a similar profile of immune recruitment into the airways, dominated by neutrophils (Fig. S5a). Quantitation of total BALF leukocytes and neutrophils also demonstrated a consistent elevation in mice expressing TLR2 on either compartment (Fig. S5b). By contrast, other innate populations displayed a different pattern in BALF compared to lung tissue. Minimal changes were observed in alveolar macrophages and DCs, but elevation of a monocyte subset (SiglecF⁻CD3⁻B220⁻CD11c⁻CD11b^{hi}Ly6C^{mid}) occurred in all groups expressing TLR2, and a significant elevation of inflammatory monocytes (SiglecF⁻CD3⁻B220⁻CD11c⁻CD11b^{hi}Ly6C^{hi}) was observed only in mice expressing TLR2 on immune cells (Fig. S5b). TLR2 expression on these cells was confirmed only in groups of mice receiving WT BM (Fig. S6). Thus, TLR2 on both respiratory epithelia and immune cells plays a role in early innate immune responses to Pam₂Cys Spike mucosal vaccination. Expression on either compartment is sufficient for neutrophil recruitment, but expression on non-immune cells leads to increased populations of antigen presenting cells, such as DC, in the lungs.

TLR2 on immune cells is required for optimal adaptive responses to mucosal Pam₂Cys Spike vaccination

To determine the impact of TLR2 expression on non-immune *versus* immune cells on the generation of adaptive immune responses, a similar experimental protocol was performed, but mice received three i.n vaccinations with Pam₂Cys Spike, each 2 weeks apart (Fig. 4a). The immune profile in the lungs was examined 1 week post final booster vaccination. Computational clustering analysis of all lung leukocytes was again performed to examine the relative expression of TLR2 and verify bone marrow replacement (Fig. 4b). At this time point after booster vaccination, clusters with the highest degree of TLR2 expression were identified as alveolar (SiglecF⁺CD11c^{hi}) and interstitial (SiglecF⁻CD64⁺CD11b^{hi}) macrophages (Fig.

S7). Manual gating in FlowJo was performed to quantitate these cells and confirm their TLR2 expression, and examine other immune cell populations of interest (Fig. S8). There was a significant increase in total lung leukocytes in groups expressing TLR2 on immune cells, and of interest, a substantial increase in both the proportion and number of T-cells, particularly CD4⁺ T-cells (Figs. 4c,d). A significant increase of B-cells (B220⁺CD11c⁻) was apparent in *Tlr2*^{-/-} mice receiving WT BM, but not in WT mice receiving WT BM. In contrast, mice without TLR2 on immune cells against either a WT or *Tlr2*^{-/-} background, had a similar profile of lymphocyte populations.

Spike antigen-specific humoral and T-cell responses were also examined. While all mice had detectable Spike-specific IgG responses in serum and BALF, expression of TLR2 on either immune or non-immune cells was required for the generation of substantial titres of IgG or IgA (Fig. 5a). There was a clear advantage in mice with expression of TLR2 on immune cells, with these groups generating significantly greater IgG and IgA titres, and importantly nAb in both serum and BALF (Fig. 5b). Consistent with this finding, while there was no change between groups in the proportion of total CD3⁺CD4⁺ cells in the mediastinal lymph node (MLN), mice with TLR2 on immune cells had a significant increase in the proportion of Bcl6⁺CD4⁺ T-cells, consistent with an increased T-follicular helper response (Fig. 5c, gating strategy in Fig. S9). In the lung tissue, Spike-specific cytokine secreting CD4⁺ T-cells again were significantly upregulated only in groups with TLR2 on immune cells, in particular IL-17A⁺ and TNF⁺ cells (Fig. 5d). Systemically in the spleen, Spike-specific cytokine-secreting CD4⁺ T-cells were detectable in all groups that expressed TLR2 on either non-immune or immune cells, but again, TLR2 expression on immune cells provided an advantage, and expression on both compartments provided the greatest response (Fig. 5e). Thus, TLR2 expression is required for the generation of consequential adaptive immune responses to the Spike protein following mucosal Pam₂Cys Spike vaccination, and expression of TLR2 on immune cells is required for optimal generation of adaptive immunity.

Pam₂Cys Spike vaccination induces sterilizing immunity against SARS-CoV-2 challenge in mice

To determine if the potent immune responses induced by Pam₂Cys Spike vaccination were protective, an *in vivo* murine model of SARS-CoV-2 infection was utilized. C57BL/6 mice expressing human ACE2 (K18-hACE2) were immunized with Pam₂Cys adjuvant alone, or Pam₂Cys Spike either s.c or i.n, three times two weeks apart. Serum was collected at one week post final vaccination, and the induction of anti-Spike IgG and IgA responses were confirmed. As in wild type C57BL/6 mice (Fig. 1b), mucosal vaccination induced superior titres and uniquely generated IgA (Fig. 6a). The neutralizing potential of these antibodies to inhibit viral infection and cytopathic effect, was first tested *in vitro* in HEK293 cells overexpressing ACE2 and TMRPSS2 (HEK-ACE2-TMPRSS2), utilizing the ancestral (A.2.2) SARS-CoV-2 strain, and also Beta and Delta variants. Substantial nAb titres were generated against the ancestral strain, and while these titres were reduced against Beta and Delta strains, mucosal immunization induced significant and superior responses, with a mean nAb EC₅₀ greater than 10³ against both VOCs (Fig. 6b).

At three weeks post final booster vaccination, mice were challenged with SARS-CoV-2 i.n, and clinical data collected for 7 days. Mice receiving Pam₂Cys Spike vaccination, by either route, were completely

protected from weight loss (Fig. 6c) and clinical indicators of disease (Fig. 6d). In contrast, mice immunized s.c with Pam₂Cys adjuvant only had no protection, however, 40% of mice receiving Pam₂Cys i.n notably did not lose weight or show clinical indicators of disease. A substantial influx of leukocytes in BALF was observed in Pam₂Cys s.c mice, including macrophages, neutrophils and lymphocytes, which were significantly reduced in the Pam₂Cys Spike s.c group. Interestingly, total leukocyte counts were reduced equivalently in both Pam₂Cys i.n and Pam₂Cys Spike i.n vaccinated mice, although neutrophils were significantly elevated in Pam₂Cys i.n mice (Fig. 6e). Consistent with the substantial antibody response generated by Pam₂Cys Spike, vaccination by either route induced sterilizing protection with no virus detected in the lung tissue at day 7 post infection (Fig. 6f). Intriguingly, 60% of mice receiving Pam₂Cys i.n also had no detectable virus in lung tissue. Consistent with these data, mice vaccinated with Pam₂Cys Spike by either route showed a marked reduction in inflammatory cell infiltration in the lung parenchyma observed by histological examination (Fig. 7). As previously observed, mice that received Pam₂Cys i.n had divergent responses, with 60% of mice displaying minimal inflammation which was comparable to those mice that were vaccinated with Pam₂Cys Spike by either route (Fig. 7). Thus, mucosal and systemic vaccination with Pam₂Cys Spike induced potent protective immunity in mice, with evidence of a non-specific beneficial effect of mucosal Pam₂Cys at this early time point after vaccination, a phenotype which has also been observed after i.n TLR2 activating lipopeptide in murine models of rhinovirus and influenza virus infection^{33–35}.

Discussion

The ability to prevent infection and spread of SARS-CoV-2, or indeed other respiratory viruses of concern such as pathogenic coronaviruses and influenza, is critical to address with vaccine development. Vaccines that only partially protect against infection, coupled with large partially immunized populations, may provide a perfect evolutionary driver for VOCs that evade vaccine immune responses with increased ability to replicate in the respiratory mucosa. It may be difficult for parenterally administered vaccines to provide complete protection from infection owing to the systemic nature of the responses induced¹. The generation of mucosal immunity, in the URT where viral replication first occurs, requires either local antigen exposure to generate mucosal immune responses, or very high plasma nAb titres that are unlikely to be maintained long term following parenteral vaccination¹². Indeed, even recovered patients do not consistently show clear evidence of protective mucosal immune responses despite having plasma antibodies, indicating distinct tissue compartmentalization of immune responses to SARS-CoV-2³⁶. Mucosal vaccines, either in isolation or as boosters for parenteral vaccination, may provide a powerful strategy to generate local protective responses in the pulmonary environment, with the potential to reduce the risk of infection and transmission.

Here, we demonstrate that vaccination with a novel protein-based subunit vaccine, Pam₂Cys Spike administered either parenterally or mucosally, led to substantial serum anti-Spike IgG titres and high nAb against SARS-CoV-2 virus, including Beta and Delta variants (Fig. 1 and Fig. 6a,b). In mice expressing

human ACE2, this resulted in complete protection against viral infection in the lung tissue and from clinical indicators of disease (Fig. 6, 7). There is strong evidence for a correlation between high serum nAb titres and protection from COVID-19³⁷, including against VOCs, supporting the benefits of booster vaccinations to maintain high serum nAb titres³⁸. Studies in non-human primates demonstrate a correlation between increasing serum nAb titres and protection in the URT, so that lower nAb titres are sufficient to protect the lung alone, compared to higher nAb levels needed to protect both the URT and lungs³⁹. Thus, while many of the currently deployed intramuscular vaccines can prevent SARS-CoV-2-induced pneumonia and severe COVID-19, there is greater variability in protection against URT infection and transmission. Importantly, Pam₂Cys Spike mucosal vaccination generated high levels of anti-Spike IgA, as well as increased nAb in both the serum and airways (Fig. 1 and Fig. 6a,b). Mucosal IgA reduces colonisation of the mucosa by other respiratory pathogens², including when induced by i.n vaccination^{30,40}. There is scope to explore the addition of defined Spike epitopes to the vaccine that may induce cross-reactive nAb against SARS-CoV-2 variants, or other pathogenic coronaviruses⁴¹. Mucosal vaccination also increased lung Spike-specific CD4⁺ T-cell responses (Fig. 2), that may contribute to the maintenance of protection. Inclusion of additional viral antigens, such as the nucleocapsid protein, to enhance T-cell immunity through broader epitope coverage^{42,43}, may sustain long-term protective memory responses in the mucosa, including in individuals with antibody deficiency. This also has the potential to provide cross-protection against other coronaviruses.

TLR2, the pattern recognition receptor activated by Pam₂Cys in this vaccine, is widely distributed in the pulmonary environment, including expression by both respiratory epithelia and antigen presenting immune cells^{24,25}. However, the relative contribution of these compartments to the mucosal vaccine response has not been defined. In our work, mice deficient in TLR2 on both the epithelia and hematopoietic compartments had minimal responses to mucosal Pam₂Cys Spike vaccination, indicating that vaccine-induced immune activation was dependent on TLR2 stimulation. After TLR2 stimulation of the pulmonary epithelia, IL-6, TNF and IL-1 may be released to recruit neutrophils and activate APCs²²⁻²⁵. Interestingly, we demonstrate here that the induction of early neutrophil responses in the lungs and airways was facilitated to the same extent by TLR2 expression on either the epithelia or immune cells (Fig. 3c). TLR2 expression on the epithelia provided an advantage for APC recruitment, including DC, alveolar macrophages and monocyte subsets (Fig. 3d). Nevertheless, the expression of TLR2 in the hematopoietic compartment was required for the optimal generation of lung-localised, antigen-specific adaptive responses after booster vaccination (Figs. 4 and 5), in particular for the strong IL-17⁺ CD4⁺ T-cell response, which is typical following mucosal delivery of protein-based vaccines⁴⁴⁻⁴⁶, particularly those activating TLR2^{26,27}.

Of interest, SARS-CoV-2 challenge following parenteral and mucosal immunization revealed that the delivery of the adjuvant Pam₂Cys by the i.n, but not the s.c route, resulted in a partial protective effect. This suggests that activation of TLR2 in the nasal and lung environment can induce antigen-independent innate immunity, even weeks after i.n delivery of Pam₂Cys. This expands the observation that a Pam₂Cys-

based, TLR2 activating lipopeptide could activate the nasal epithelium and immune cells to protect against rhinovirus and influenza virus infection^{33–35}. The method of delivery and volume of the vaccine may influence whether the immune activation occurs in the upper airways alone or the upper and lower respiratory tract. This is important for consideration of clinical translation, as i.n vaccination in humans typically delivers the vaccine primarily to the upper airways¹². Prophylactic i.n delivery of a TLR2 agonist has recently been demonstrated to protect against URT viral shedding of SARS-CoV-2 in a ferret model⁴⁷, and early clinical trials are underway to assess safety and tolerability in humans (ACTRN12621000607875p). This provides further support for Pam₂Cys as a promising mucosal adjuvant for enhancing both local innate defences and induction of powerful adaptive immunity.

Currently, at least eight mucosal vaccines for COVID-19 have entered clinical trials, delivered either exclusively intra-nasally or by aerosol, or as a mucosal booster following parenteral prime⁴⁸. Only one of these is a mucosal protein-based vaccine (utilising a receptor-binding domain recombinant protein, clinical trial RPCEC00000345), with the others being live-attenuated or viral vector-based formulations designed to express the Spike protein¹². The induction of immunity to the viral vector itself will limit the use of the latter vaccines to boost immunity. As there will be an ongoing requirement for boosting the waning nAb levels to currently used COVID-19 vaccines, and subunit protein-based vaccines with safe and effective adjuvants, such as Pam₂Cys Spike, will provide a safe alternative for delivery to the nasal mucosa in a needleless fashion.

Future studies will require an assessment of the durability of protective responses achievable with this vaccination approach, including in the URT such as the nasal mucosa and trachea, for which SARS-CoV-2 demonstrates a notable tropism⁴⁹. In animal models of influenza, resident memory cells generated in the nasal passages show potential for preventing virus dissemination to the lung⁵⁰. In addition, other animal models, such as hamsters or ferrets, could be used to determine the impact of vaccination on transmission to naïve animals^{31,51}. As a large proportion of the world's population has received, or will receive, an intramuscular vaccination for SARS-CoV-2, it will be important to test a “prime-pull” vaccination approach^{12,52}. Memory T-cells induced by parenteral vaccination can be recruited to mucosal sites by subsequent mucosal boosting⁵³, providing a strategy to optimise both systemic IgG and T-cell responses that protect the lower respiratory tract from severe disease, as well as appropriate mucosal immunity to prevent infection. Thus, the mucosal vaccination strategy described here has the potential to generate IgA-secreting memory B-cells and tissue resident T-cells in the respiratory tract, to provide protection from viral infection and reduce the risk of ongoing viral transmission with pandemic potential.

Methods

Vaccine production

Vaccine adjuvant was Pam₂Cys-SK₄-triethylene glycolate (Pam₂Cys) as previously described^{27,54}. SARS-CoV-2 Spike HexaPro expression vector was a gift from Jason McLellan (Addgene plasmid # 154754 ;

<http://n2t.net/addgene:154754> ; RRID:Addgene_154754)⁵⁵. The HexaPro variant contains six beneficial proline substitutions providing ~10-fold higher expression than the parental construct and increased stability of the trimer in prefusion conformation. Hrv3C-His-Strep tags were included for purification purposes. Recombinant Spike protein was expressed in suspension-adapted Expi293F™ cells, harvested, and purified by immobilised metal affinity chromatography (IMAC) using Ni-NTA agarose as previously described⁵⁶. The eluate following IMAC was dialysed to 2 mM Tris, pH 8.0, 200 mM NaCl, concentrated before being passed through a 0.22 µm filter, and subjected to gel filtration chromatography using HiLoad 16/600 Superdex 200 (Cytiva) in 2 mM Tris, pH 8.0, 200 mM NaCl. Doses per vaccination were as follows: 7.7 µg Pam₂Cys-SK₄-triethylene glycolate and 6 µg Spike, admixed in sterile cell culture grade phosphate buffered saline, endotoxin tested (PBS; Sigma D8537).

Mouse strains and immunization procedures

All animal experiments were conducted in full compliance with local and institutional guidelines, with approvals from the Sydney Local Health District Animal Welfare Committee (2020-003, 2020-019). These adhere to the Australian Code for the Care and Use of Animals for Scientific Purposes (2021) as set out by the National Health and Medical Research Council of Australia. Mice had access to standard rodent chow and water ad libitum. Female C57BL/6 (6-8 week-old) or BALB/c (various ages) mice were sourced from Animal BioResources (Mossvale, Australia) and housed at the Centenary Institute under specific-pathogen-free conditions. Female *Tlr2*^{-/-} mice (BALB/c background) were bred at the Centenary Institute^{24,25}. Female K18-hACE2 mice⁵⁷ were sourced from the Jackson Laboratory and bred at Australian BioResources and the Centenary Institute. For s.c injection, mice were anaesthetized with gaseous isoflurane (4%, O₂ 1 L/min) and injected at the base of tail with vaccine in a maximum of 200 µl volume. For i.n instillation, mice were either anaesthetized by intraperitoneal injection of ketamine/xylazine (50 mg/6.25 mg/kg) or gaseous isoflurane, then vaccine in 30-50 µL of PBS was applied to the nares such that mice inhaled the solution. For assessment of early innate responses mice were immunized once; for immunogenicity or protection studies mice were immunized three times 2 weeks apart and adaptive immune responses assessed 1 week after the last booster vaccination.

Generation of TLR2 chimeric mice

WT BALB/c or *Tlr2*^{-/-} female mice (between 6-17 weeks of age, similar aged WT and *Tlr2*^{-/-} mice were compared in each experiment) were irradiated at a caesium source (800 RAD). Femurs were isolated aseptically from donor BALB/c or *Tlr2*^{-/-} female mice into complete culture media, RPMI Glutamax (Gibco) with 10% FBS (Hyclone) and penicillin-streptomycin (100 U/ml; Gibco). Marrow cells were flushed from the femur with a 25G needle into complete media, 70 µm filtered and erythrocytes lysed with red blood cell lysing buffer Hybri-Max (Sigma). Cells were 70 µm filtered again before washing and suspending in PBS for i.v injection of 1.8 x10⁶ cells (in 200 µl) per mouse. Mice were rested for 12 weeks to allow hematopoietic reconstitution. For the first 3 weeks post irradiation, mice received prophylactic antibiotics (Trivetin; final concentration in drinking water 0.54 mg/ml trimethoprim and 2.7 mg/ml

sulfadoxine) and extra dietary supplements (sunflower seeds, DietGel® Boost - Clear H₂O) as supportive care.

Organ collection and processing

Mice were euthanized by CO₂ asphyxiation, tissues collected aseptically and maintained at 4°C. Blood was collected by rupture of the inferior vena cava/portal vein and allowed to clot, before collection of sera after centrifugation (2000 xg, 15 min). BALF was obtained by tracheal intubation, inflation of the airways with 1 ml PBS and collection of the fluid. Cells were isolated by centrifugation, and BALF was immediately frozen to preserve for further analyses. Other tissues were collected into RPMI 1640 (Gibco) supplemented with 10% FCS (Sigma), 2-ME (0.05 mM), and penicillin–streptomycin (100 U/mL; Gibco). For lung tissue, circulating blood was removed by perfusion with PBS and heparin (20 U/mL; Sigma) injected into the right atrium of the heart. Lung lobes were diced and digested at 37°C for 45 min with collagenase type 4197 (50 U/mL; Sigma) and DNase I (13 µg/mL; Sigma), then filtered through a 70 µm sieve. Mediastinal lymph nodes and spleens were pressed through a 70 µm filter and the leukocytes pelleted by centrifugation. Erythrocytes were lysed with red blood cell lysing buffer Hybri-Max (Sigma), and leukocytes enumerated with Trypan Blue (0.04%) exclusion by hemocytometer.

Quantitation of anti-spike IgG and IgA

Spike-specific IgG and IgA in serum and BALF were determined by indirect ELISA. High-binding ELISA plates (Corning Falcon) were coated overnight at 4°C with Spike protein (1 µg/ml) in carbonate/bicarbonate coating buffer (0.05 M, pH 9.6). Plates were washed with PBS (POCD) plus 0.05% (v/v) Tween 20 (Sigma), then blocked with 1% (w/v) BSA (Bovogen) in PBS (1 h at 37°C). Dilution series of sera (from 1:100) or BALF (from 1:40) were added (1 h at 37°C) to capture Spike-specific antibody, and then after washing, detected with either horseradish peroxidase-conjugated goat anti-mouse IgG (Invitrogen Novex, cat# A16090, used at 1:2000) or goat anti-mouse IgA (Invitrogen, cat# 626720, used at 1:2000). Washed plates were developed with tetramethylbenzidine substrate (Sigma), stopped with 2 M HCl, and then absorbance read at 450 nm with a 570 nm reference wavelength (Tecan Infinite M1000 PRO). The titre was estimated by the titration curve of each sample interpolated with the mean absorbance (+ 3SD) of the relevant negative samples from unvaccinated mice (1:100 sera, or 1:40 BALF).

Cell lines for infection assays

HEK293T (ATCC CRL-3216) and VeroE6 (ATCC CRL-1586) cells were maintained in Dulbecco's Modified Eagle Medium (DMEM; Invitrogen) or Minimal Essential Media (MEM; Invitrogen) supplemented with 10% FBS and 100 µg/mL Penicillin-Streptomycin (Gibco), and sub-cultured according to the supplier's instructions. HEK293T cells stably expressing human ACE2 and/or TMPRSS2 were generated by transducing cells with lentiviral particles and clonal selection as previously described⁵⁸. Cell lines were routinely checked for mycoplasma contamination (MycoAlert™ PLUS Mycoplasma Detection Kit; Lonza) and confirmed as negative.

Quantitation of nAb titres using a pseudovirus assay

nAbs were quantitated against replication-deficient SARS-CoV-2 ancestral (Wuhan) Spike pseudotyped lentivirus particles as previously described⁵⁹. Briefly, pseudovirus particles were generated by co-transfecting a Spike expression construct pCG1-SARS-2-S Δ 18^{60,61} and GFP-luciferase vector with lentivirus packaging and helper plasmids into HEK293T cells, using Eugene HD (Promega)⁶². Pseudovirus particles were incubated with serially diluted serum or BALF samples at 37°C, 5% CO₂ for 1 hr prior to spinoculation (800 xg, 35°C) of ACE2 over-expressing HEK293T cells. Seventy-two hr post-transduction, cells were fixed and stained with Hoechst 33342 (NucBlue™ Live ReadyProbes™ Reagent, Invitrogen) as per the manufacturers instructions, and imaged using the Opera Phenix high content screening system (Perkin Elmer). The percentage of GFP positive cells was enumerated (Harmony® high-content analysis software, Perkin Elmer) and neutralising endpoint titre determined as the dilution required for $\geq$ 50% inhibition of infection (EC₅₀), estimated by sigmoidal curve and interpolation in GraphPad Prism software.

Quantitation of nAb titres against SARS-CoV-2

High-content fluorescence microscopy was used to determine the neutralising capacity of serum and BALF from vaccinated mice to inhibit live SARS-CoV-2 ancestral virus (A.2.2) infection and the resulting cytopathic effect in permissive cells (VeroE6, final MOI=0.05), as previously described⁶⁰. Alternatively, Beta (B.1.351) and Delta (B.1.617.2) variants were compared against ancestral virus (A.2.2) in HEK293 cells overexpressing ACE2 and TMPRSS2^{58,60}. The neutralisation endpoint titre of diluted serum or BALF samples was set to $\geq$ 50% neutralisation (EC₅₀), estimated by sigmoidal curve and interpolation in GraphPad Prism software. All work utilising SARS-CoV-2 virus was performed in PC3/BSL3 facilities.

Flow cytometry and ex vivo antigen recall of leukocytes

Lung, BALF, spleen or mediastinal lymph node single cell suspensions were immunolabelled to facilitate phenotyping and data acquired by flow cytometry. Briefly, after washing in PBS, cells were incubated with live/dead fixable blue dead cell stain (Invitrogen) and Fc receptors blocked with anti-mouse CD16/CD32 (2.4G2; BD Biosciences). After washing in FACS wash (PBS with 2% FCS and 2 mM EDTA), surface markers were labelled. For lung and BAL immune profiling, antibodies were anti-mouse B220-BUV737 (RA3-6B2; BD), SiglecF-BV421 (E50-2440; BD), MHCII-V500 (M5/114.15.2; BD), Ly6G-BV650 (1A8; Biolegend), CD11b-BV785 (M1/70; Biolegend), CD45.2-FITC (104; BD), CD11c-PE (N418; Biolegend), CD3-PECF594 (145-2C11; BD), CD64-PECy7 (X54-5/7.1; Biolegend), TLR2-AF647 (6C2; BD), CD4-AF700 (RM4-5; Biolegend) or CD4-AF700 (GK1.5; eBioscience), and Ly6C-APCCy7 (HK1.4; Biolegend). For mediastinal lymph nodes, cells were first incubated with Fc receptor blocking anti-mouse CD16/CD32 (2.4G2; BD Biosciences) and anti-CXCR5-biotin (2G8; BD) at 37 °C for 40 min, washed in PBS, then incubated with live/dead fixable blue dead cell stain (Invitrogen) and streptavidin-PE (BD) in PBS for 20 min at 4 °C. Cells were then surface immunostained with anti-mouse PD1-BV785 (29F1A12; Biolegend), CD3-PECF594 (145-2C11; BD), CD44-PECy7 (IM7; BD), CD4-AF700 (RM4-5; Biolegend) or CD4-AF700 (GK1.5; eBioscience), and CD8-APCCy7 (53-6.7; BD). Transcription factor staining with anti-mouse Bcl6-AF647

(K112-91; BD) was performed using eBioscience FoxP3/Transcription Factor staining buffer set (Invitrogen), according to the manufacturer's instructions.

Enumeration of Spike-specific T-cell responses was performed by *ex vivo* antigen recall, intra-cytoplasmic staining and flow cytometry. Lung or spleen leukocytes were stimulated for 4 hr (37°C, 5% CO₂) with Spike protein (5 µg/ml), or for controls media alone, or anti-mouse CD3 (1452C11; 5 µg/mL) and anti-mouse CD28 (37.51; 5 µg/mL; BD Pharmingen). Brefeldin A (10 µg/mL; Sigma) was added and further incubated such that cytokine accumulated intracellularly (12 h, 37°C, 5% CO₂). Viability stain and Fc blocking was performed, then surface markers were immunolabelled with anti-mouse CD8-APCCy7 (53-6.7; BD Pharmingen), CD4-AF700 (RM4-5; Biolegend) or CD4-AF700 (GK1.5; eBioscience) and CD44-PECy7 (IM7; BD) and then cells were washed thoroughly. Cells were fixed with BD Cytofix/perm followed by thorough washing with BD Perm/Wash. Intracellular cytokines were labelled with anti-mouse IFN γ -FITC (XMG1.2; BD Pharmingen), IL-17A-PB (TC11-18H10.1; Biolegend), IL-4-PE (11B11; BD), TNF-PerCPCy5.5 (MP6-XT22; BD), and IL-2-APC (JES6-5H4; Biolegend) prepared in BD Perm/Wash buffer and then washed. Compensation controls were prepared in the same manner as experimental samples, viability stain was prepared from murine leukocytes, and UltraComp eBeads Compensation Beads (Invitrogen) were stained with the same antibody used in experimental panels. Samples were acquired using an LSRII 5L flow analyzer (BD Biosciences).

Computational analysis of lung leukocytes was performed using the Spectre R package³², with instructions and source code provided at <https://github.com/ImmuneDynamics/spectre>. Compensated sample data were initially prepared in FlowJo (BD) with quality control gating to exclude debris and dead cells, then the CD45⁺ population was exported as raw value CSV files. Arcsinh transformation was performed on the data in R using a co-factor of 1,000 to redistribute the data on a linear scale and compress low end values near zero. The dataset was then merged into a single data.table, with keywords denoting the sample, group and cell numbers. The FlowSOM algorithm⁶³ was then run on the merged dataset to cluster the data into 30 clusters, where every cell is assigned to a specific cluster and metacluster. Subsequently, the data were downsampled and analysed by the dimensionality reduction algorithm Fit-SNE for cellular visualisation⁶⁴. Alternatively, flow cytometry data were analysed with FlowJo (v10; BD), see Figs. S1, 3, 8 and 9 for gating strategies.

SARS-CoV-2 murine challenge model and organ collection

Mice were housed in a PC3/BSL3 facility in an IsoCage N biocontainment system (Tecniplast, Italy). Three weeks after final i.n vaccination, female K18-hACE2 mice were anaesthetised with gaseous isoflurane and infected i.n with 10³ plaque forming units (PFU) of SARS-CoV-2 (VIC01/2020) in 30 µl final volume as previously described⁶⁵. Clinical indicators of disease, including weight, were monitored for the following 7 days. Clinical signs were classified into four categories based on the following criteria: No clinical score - mice did not exhibit any clinical symptoms; Category 1 – weight loss, early lethargy and hunching; Category 2 – substantial weight loss, lethargy, hunching, ruffling and early laboured breathing; Category 3 – all signs in Category 2 are exacerbated, accompanied by immobility. Mice were euthanised

with intraperitoneal overdose of pentobarbitone (Virbac, Australia). The multi-lobe lungs were tied off using surgical thread and BALF was collected from the single lung lobe via lavage with 1 mL HANKS solution (Sigma-Aldrich, USA) with a blunted 19-gauge needle inserted into an incision above the largest cartilage ring of the trachea. BALF was centrifuged (300 xg, 4 °C, 7 min), and supernatants were collected and snap frozen. The remaining cell pellet was resuspended in 200 µL Red Blood Cell Lysis Buffer (ThermoFisher, USA) for 5 min, followed by addition of 700 µL HANKS solution and then centrifuged again. Following centrifugation, the supernatant was discarded and the cell pellet was resuspended in 160 µL HANKS solution and enumerated using a haemocytometer (Sigma-Aldrich, USA). Differential BALF counts were performed by depositing 70 µL of BALF leukocytes into a cytospin funnel and then centrifuging onto a glass slide (300 xg, 7 min). Slides were left to air-dry overnight, after which they were stained using Quick Dip Stain Kit (Modified Giemsa Stain) protocol as per manufacturer's instructions (POCD Scientific, Australia). Differential counts were determined based on cellular morphology and staining using light microscopy with a Primovert Zeiss Microscope under a 20X objective (Zeiss, Germany). Multi-lobe lungs were collected and snap frozen on dry ice. Lung homogenates were prepared fresh, with the third lobe of the multi-lobe lungs placed into a gentle MACS C-tube (Miltenyi Biotec, Australia) containing 2 mL HANKS solution. Lung tissue was homogenised using a gentleMACS tissue homogeniser, followed by centrifugation (300 xg, 7 min) to pellet cells, and collection of supernatants for plaque assays. The single lobe lungs were perfused with 0.9% NaCl solution via the heart, followed by inflation with 0.5 mL 10% neutral buffered formalin (Sigma-Aldrich, USA) through the tracheal incision, and placed into a tube containing 10% neutral buffered formalin. Lung lobes were fixed in formalin for at least 2 weeks after which, single lung lobes were transported to a PC2 facility for paraffin-embedding prior to being cut into 3 µm thick sections using a Leica microtome (Leica, Germany). Histology sections were stained using Quick Dip Stain Kit (Modified Giemsa Stain) protocol as per manufacturer's instructions (POCD Scientific, Australia). Inflammatory cells in single lobe lungs were counted using a Zeiss Axio Imager.Z2 microscope with a 40X objective (Zeiss, Germany).

Plaque assays

Plaque forming units (PFU) of SARS-CoV-2 viral titres were quantitated in VeroE6 cells⁶⁵. Cells were deposited into a 24-well cell culture plate at 1.5×10^5 cells/well in a 0.5 mL volume and allowed to adhere overnight. The next day, virus-containing samples from lung homogenates were serially diluted in MEM cell culture medium and cell culture supernatants removed from the VeroE6 cells and 250 µL of virus-containing samples was added to the surface of the cell monolayers. Plates were placed in the cell culture incubator (37°C/5%CO₂) and rocked gently every 15 min to facilitate viral adhesion. Following 1 hr incubation, 250 µL of 0.6% agar/MEM solution was overlaid gently onto the cell culture samples and placed into the incubator. At 3 days post-infection, an equal volume of 8% paraformaldehyde solution (4% final solution) was added to all wells and incubated at room temperature for 30 min. Following fixation, the supernatant was discarded and the cell monolayer washed twice with PBS, followed by incubation with 0.025% crystal violet solution (Sigma-Aldrich, USA) for 5 min at room temperature and then two additional washes with PBS prior to revealing viral plaques.

Statistics

The significance of differences between two experimental groups was evaluated by two-tailed Welch's t test or Mann-Whitney test. Multiple experimental groups were compared by Kruskal-Wallis test or two-way analysis of variance (ANOVA), with pairwise comparisons achieved using Dunn's or Tukey's post-hoc multiple comparisons test. Differences were considered statistically significant when $p \leq 0.05$, exact values are indicated.

Declarations

Data availability

The datasets generated during and/or analysed in the current study are available from the corresponding author on reasonable request.

Author contributions

A.S.A, J.W.C.M, R.J.P and W.J.B initiated and designed the research studies. A.S.A, J.W.C.M, M.D.J, C.L.A, A.A, R.S, S.M, D.H.N, C.C, S.T, conducted experiments and acquired data. J.W.C.M, R.S, J.P.M, C.C, S.N.B, S.T, M.S, J.A.T, P.M.H provided reagents and designed or established critical assays utilised. A.S.A, S.N.B, P.M.H, R.J.P, and W.J.B interpreted and analyzed data. A.S.A wrote the manuscript with contributions from all authors.

Acknowledgements

This work was supported by grants from the National Health and Medical Research Council APP1153493 (to W.J.B), APP2011467 (to W.J.B and M.D.J), APP1175134 (to P.M.H) and APP1174941 (to R. J. P.), the Medical Research Future Fund (to M.S and J.A.T), the Rainbow Foundation, NSW RNA Biology hub and UTS (to P.M.H), the University of Sydney Drug Discovery Initiative and the University of Sydney Institute for Infectious Diseases (to A.S.A and M.S) and the Kenyon Foundation (to M.D.J). We acknowledge the assistance of Dr David McDonald in production of adjuvant stocks, Dr Charles Bailey for supply of lentivirus constructs, the support of Sydney Cytometry and the animal facility at the Centenary Institute. Figure 1A was partly created with BioRender.com.

Competing interests

The authors declare that no competing interests exist.

References

1. Krammer, F. SARS-CoV-2 vaccines in development. *Nature* **586**, 516–527 (2020).
2. Renegar, K. B., Small, P. A., Boykins, L. G. & Wright, P. F. Role of IgA versus IgG in the Control of Influenza Viral Infection in the Murine Respiratory Tract. *The Journal of Immunology* **173**, 1978–

- 1986, doi:10.4049/jimmunol.173.3.1978 (2004).
3. Bergwerk, M. *et al.* Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. *New England Journal of Medicine* **385**, 1474–1484, doi:10.1056/NEJMoa2109072 (2021).
 4. Levin, E. G. *et al.* Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. *New England Journal of Medicine*, doi:10.1056/NEJMoa2114583 (2021).
 5. Bayart, J.-L. *et al.* Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers. *Vaccines* **9**, 1092 (2021).
 6. European Centre for Disease Prevention and Control. Implications of the emergence and spread of the SARSCoV-2 B.1.1. 529 variant of concern (Omicron), for the EU/EEA. 26 November 2021. ECDC: Stockholm; 2021.
 7. Keehner, J. *et al.* Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce. *The New England journal of medicine* **385**, 1330–1332, doi:10.1056/NEJMc2112981 (2021).
 8. Pouwels, K. B. *et al.* Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. *medRxiv*, 2021.2008.2018.21262237, doi:10.1101/2021.08.18.21262237 (2021).
 9. Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z. & Pierce, B. F. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. *Nature Reviews Immunology* **21**, 626–636, doi:10.1038/s41577-021-00592-1 (2021).
 10. Lavelle, E. C. & Ward, R. W. Mucosal vaccines – fortifying the frontiers. *Nature Reviews Immunology*, doi:10.1038/s41577-021-00583-2 (2021).
 11. Wang, Z. *et al.* Enhanced SARS-CoV-2 neutralization by dimeric IgA. *Science Translational Medicine* **13**, eabf1555, doi:doi:10.1126/scitranslmed.abf1555 (2021).
 12. Lund, F. E. & Randall, T. D. Scent of a vaccine. *Science* **373**, 397–399, doi:doi:10.1126/science.abg9857 (2021).
 13. Hassan, A. O. *et al.* An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. *Cell Reports* **36**, doi:10.1016/j.celrep.2021.109452 (2021).
 14. Hassan, A. O. *et al.* A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. *Cell Reports Medicine* **2**, doi:10.1016/j.xcrm.2021.100230 (2021).
 15. Bricker, T. L. *et al.* A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. *Cell Reports* **36**, doi:10.1016/j.celrep.2021.109400 (2021).
 16. Hassan, A. O. *et al.* A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. *Cell* **183**, 169-184.e113, doi:10.1016/j.cell.2020.08.026 (2020).
 17. Doremalen, N. v. *et al.* Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. *Science Translational Medicine* **13**,

- eabh0755, doi:doi:10.1126/scitranslmed.abh0755 (2021).
18. Park, J.-G. *et al.* Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2. *iScience* **24**, doi:10.1016/j.isci.2021.102941 (2021).
 19. Gallo, O., Locatello, L. G., Mazzoni, A., Novelli, L. & Annunziato, F. The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. *Mucosal Immunology* **14**, 305–316, doi:10.1038/s41385-020-00359-2 (2021).
 20. Nanishi, E. *et al.* An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor-binding domain vaccine in aged mice. *Science Translational Medicine* **0**, eabj5305, doi:10.1126/scitranslmed.abj5305.
 21. Kiyono, H. & Fukuyama, S. NALT- versus PEYER'S-patch-mediated mucosal immunity. *Nature Reviews Immunology* **4**, 699–710, doi:10.1038/nri1439 (2004).
 22. de Oliveira Nascimento, L., Massari, P. & Wetzler, L. The Role of TLR2 in Infection and Immunity. *Frontiers in immunology* **3**, doi:10.3389/fimmu.2012.00079 (2012).
 23. Andersson, M. *et al.* Mycobacterium bovis bacilli Calmette-Guerin regulates leukocyte recruitment by modulating alveolar inflammatory responses. *Innate Immunity* **18**, 531–540, doi:10.1177/1753425911426591 (2012).
 24. Haw, T. J. *et al.* Toll-like receptor 2 and 4 have opposing roles in the pathogenesis of cigarette smoke-induced chronic obstructive pulmonary disease. *American Journal of Physiology-Lung Cellular and Molecular Physiology* **314**, L298-L317, doi:10.1152/ajplung.00154.2017 (2018).
 25. Beckett, E. L. *et al.* TLR2, but Not TLR4, Is Required for Effective Host Defence against Chlamydia Respiratory Tract Infection in Early Life. *PloS one* **7**, e39460, doi:10.1371/journal.pone.0039460 (2012).
 26. Hanna, C. C. *et al.* Synthetic protein conjugate vaccines provide protection against *Mycobacterium tuberculosis* in mice. *Proceedings of the National Academy of Sciences* **118**, e2013730118, doi:10.1073/pnas.2013730118 (2021).
 27. Ashhurst, A. *et al.* Mucosal vaccination with a self-adjuvanted lipopeptide is immunogenic and protective against Mycobacterium tuberculosis. *J. Med. Chem.* **62**, 8080–8089, doi:10.1021/acs.jmedchem.9b00832 (2019).
 28. Tyne, A. S. *et al.* TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines. *Vaccine* **31**, 4322–4329 (2013).
 29. Zeng, W., Ghosh, S., Lau, Y. F., Brown, L. E. & Jackson, D. C. Highly Immunogenic and Totally Synthetic Lipopeptides as Self-Adjuvanting Immunocontraceptive Vaccines. *The Journal of Immunology* **169**, 4905–4912, doi:10.4049/jimmunol.169.9.4905 (2002).
 30. Batzloff, M. R., Hartas, J., Zeng, W., Jackson, D. C. & Good, M. F. Intranasal Vaccination with a Lipopeptide Containing a Conformationally Constrained Conserved Minimal Peptide, a Universal T Cell Epitope, and a Self-Adjuvanting Lipid Protects Mice from Group A Streptococcus Challenge and Reduces Throat Colonization. *J. Infect. Dis.* **194**, 325–330, doi:10.1086/505146 (2006).

31. Johansen, M. D. *et al.* Animal and translational models of SARS-CoV-2 infection and COVID-19. *Mucosal Immunology* **13**, 877–891, doi:10.1038/s41385-020-00340-z (2020).
32. Ashhurst, T. M. *et al.* Integration, exploration, and analysis of high-dimensional single-cell cytometry data using Spectre. *Cytometry Part A* **n/a**, 1-17, doi:https://doi.org/10.1002/cyto.a.24350 (2021).
33. Deliyannis, G. *et al.* TLR2-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs. *JCI Insight* **6**, doi:10.1172/jci.insight.140267 (2021).
34. Tan, A. C. L. *et al.* Intranasal Administration of the TLR2 Agonist Pam2Cys Provides Rapid Protection against Influenza in Mice. *Molecular Pharmaceutics* **9**, 2710–2718, doi:10.1021/mp300257x (2012).
35. Girkin, J. *et al.* TLR2-mediated innate immune priming boosts lung anti-viral immunity. *Eur Respir J* **58**, doi:10.1183/13993003.01584-2020 (2021).
36. Smith, N. *et al.* Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection. *Nature immunology*, doi:10.1038/s41590-021-01028-7 (2021).
37. Khoury, D. S. *et al.* Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* **27**, 1205–1211, doi:10.1038/s41591-021-01377-8 (2021).
38. Cromer, D. *et al.* Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. *The Lancet Microbe*, doi:10.1016/S2666-5247(21)00267-6.
39. Corbett, K. S. *et al.* Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. *Science* **373**, eabj0299, doi:doi:10.1126/science.abj0299 (2021).
40. Oh, J. E. *et al.* Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA. *Science Immunology* **6**, eabj5129, doi:doi:10.1126/sciimmunol.abj5129 (2021).
41. Burnett, D. L. *et al.* Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability. *Immunity*, doi:10.1016/j.immuni.2021.10.019 (2021).
42. Matchett, W. E. *et al.* Cutting Edge: Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity. *The Journal of Immunology* **207**, 376, doi:10.4049/jimmunol.2100421 (2021).
43. Heitmann, J. S. *et al.* A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. *Nature*, doi:10.1038/s41586-021-04232-5 (2021).
44. Zygmunt, B. M., Rharbaoui, F., Groebe, L. & Guzman, C. A. Intranasal Immunization Promotes Th17 Immune Responses. *The Journal of Immunology* **183**, 6933–6938, doi:10.4049/jimmunol.0901144 (2009).
45. Orr, M. T. *et al.* Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy. *Vaccine* **33**, 6570–6578, doi:http://dx.doi.org/10.1016/j.vaccine.2015.10.115 (2015).

46. Counoupas, C. *et al.* Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis. *npj Vaccines* **5**, 105, doi:10.1038/s41541-020-00255-7 (2020).
47. Proud, P. C. *et al.* Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model. *EBioMedicine* **63**, doi:10.1016/j.ebiom.2020.103153 (2021).
48. Wu, S. *et al.* Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. *The Lancet Infectious Diseases*, doi:10.1016/S1473-3099(21)00396-0.
49. Nakayama, T. *et al.* Determinants of SARS-CoV-2 entry and replication in airway mucosal tissue and susceptibility in smokers. *Cell Reports Medicine* **2**, doi:10.1016/j.xcrm.2021.100421 (2021).
50. Pizzolla, A. *et al.* Resident memory CD8⁺ T cells in the upper respiratory tract prevent pulmonary influenza virus infection. *Science Immunology* **2**, eaam6970, doi:10.1126/sciimmunol.aam6970 (2017).
51. Muñoz-Fontela, C. *et al.* Animal models for COVID-19. *Nature* **586**, 509–515, doi:10.1038/s41586-020-2787-6 (2020).
52. Lapuente, D. *et al.* Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. *Nat Commun* **12**, 6871, doi:10.1038/s41467-021-27063-4 (2021).
53. Shin, H. & Iwasaki, A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. *Nature* **491**, 463–467, doi:10.1038/nature11522 (2012).
54. McDonald, D. M. *et al.* Synthesis of a Self-Adjuvanting MUC1 Vaccine via Diselenide-Selenoester Ligation-Deselenization. *ACS chemical biology*, doi:10.1021/acscchembio.8b00675 (2018).
55. Hsieh, C.-L. *et al.* Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. *Science (New York, N.Y.)* **369**, 1501–1505, doi:10.1126/science.abd0826 (2020).
56. Loo, L. *et al.* LRRC15 suppresses SARS-CoV-2 infection and controls collagen production. *bioRxiv*, 2021.2011.2009.467981, doi:10.1101/2021.11.09.467981 (2021).
57. McCray, P. B., Jr. *et al.* Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. *J Virol* **81**, 813–821, doi:10.1128/jvi.02012-06 (2007).
58. Ashhurst, A. S. *et al.* Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L. *J Med Chem*, doi:10.1021/acs.jmedchem.1c01494 (2021).
59. Counoupas, C. *et al.* Neutralising antibodies against the SARS-CoV-2 Delta variant induced by Alhydroxyquim-II-adjuvanted trimeric spike antigens. *bioRxiv*, 2021.2008.2018.456891, doi:10.1101/2021.08.18.456891 (2021).
60. Tea, F. *et al.* SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. *PLoS Med* **18**, e1003656, doi:10.1371/journal.pmed.1003656 (2021).

61. Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280.e278, doi:10.1016/j.cell.2020.02.052 (2020).
62. Norman, A. *et al.* Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display. *ACS Central Science* **7**, 1001–1008, doi:10.1021/acscentsci.0c01708 (2021).
63. Van Gassen, S. *et al.* FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data. *Cytometry Part A* **87**, 636–645, doi:https://doi.org/10.1002/cyto.a.22625 (2015).
64. Linderman, G. C., Rachh, M., Hoskins, J. G., Steinerberger, S. & Kluger, Y. Fast interpolation-based t-SNE for improved visualization of single-cell RNA-seq data. *Nature Methods* **16**, 243–245, doi:10.1038/s41592-018-0308-4 (2019).
65. Counoupas, C. *et al.* A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection. *npj Vaccines* **6**, 143, doi:10.1038/s41541-021-00406-4 (2021).

Figures

Figure 1

Vaccination with Pam₂Cys Spike induces potent Spike-specific neutralising antibody responses, which is enhanced in the airways with mucosal vaccination. **(a)** Experimental outline. C57BL/6 mice were immunized with Pam₂Cys and Spike protein s.c (blue) or i.n (red) three times, two weeks apart. Immunogenicity was assessed one week post final vaccination. Control mice were unvaccinated (UNV; black). **(b)** Anti-spike IgG and IgA titres (log₁₀ scale) in the serum and broncho-alveolar lavage fluid (BALF), determined by ELISA, using the mean +3SD of the level in 1:100 dilution of sera or 1:40 BALF from unvaccinated mice as the cut-off. **(c)** Neutralizing antibody (nAb) titres (log₁₀ scale) in the serum and BALF of vaccinated mice were determined as the titre needed for 50% inhibition of SARS-CoV-2 Spike-expressing lentivirus in HEK293-ACE2 cells, and **(d)** 50% inhibition of SARS-CoV-2 infection in

VeroE6 cells. Limits of detection are indicated by the dotted lines. Data are for individual mice from two independent biological experiments (n=2-3 each), means $\pm$ SEM are shown. Statistics: p-values indicated, (b) Welch's t test, (c, d) Kruskal-Wallis test, Dunn's multiple comparisons.

Figure 2

Mucosal vaccination induces potent lung-localised and circulating IL-17-producing Spike-specific CD4⁺ T-cells. C57BL/6 mice were immunized with Pam₂Cys Spike s.c (blue) or i.n (red) three times, two weeks apart. Control mice were unvaccinated (UNV; black). At one week post final vaccination, the frequency of antigen-specific cytokine-producing CD4⁺ T-cells in (a) the lungs and (b) spleen, or CD8⁺ T-cells in (c) the lungs and (d) spleen, were determined by intra-cellular staining and flow cytometry following recall stimulation *ex vivo* with Spike protein in the presence of Brefeldin A. Data are for individual mice from two independent biological experiments (n=3 each), means $\pm$ SEM are shown. Statistics: p-values indicated, two-way ANOVA with Tukey's multiple comparisons test.

Figure 3

TLR2 expression by both hematopoietic and non-hematopoietic lineages contribute to early innate immune responses to mucosal vaccination with Pam₂Cys Spike. **(a)** Experimental outline. *Tlr2*^{-/-} (KO) or wild type (WT) mice (n=6) were irradiated then received transfer of *Tlr2*^{-/-} or WT bone marrow (BM) cells intravenously (i.v). Mice were rested for 12 weeks to allow hematopoietic reconstitution and replacement, then immunized once with Pam₂Cys Spike intra-nasally. Immune cells in the lungs were characterized at

24 hours post vaccination. **(b)** To verify bone marrow replacement, unsupervised clustering of lung CD45⁺ cells was performed on flow cytometry data and relative expression of TLR2 was examined by Flt-SNE for each experimental group. **(c)** Mean proportions of CD45⁺ cell populations in the lungs were determined by flow cytometry, with **(d)** quantitation of populations of interest. Data are for individual mice (n=6), means $\pm$ SEM are shown. Statistics: p-values indicated, Kruskal-Wallis test, Dunn's multiple comparisons.

Figure 4

TLR2 expression by the hematopoietic lineage is required for optimal T-cell responses in the lung following mucosal vaccination and boosting with Pam₂Cys Spike. **(a)** Experimental outline. *Tlr2*^{-/-} (KO) or wild type (WT) mice were irradiated then received transfer of *Tlr2*^{-/-} or WT bone marrow (BM) cells i.v. Mice were rested for 12 weeks to allow hematopoietic reconstitution and replacement, then immunized with Pam₂Cys Spike intra-nasally three times, two weeks apart. Immune responses in the lungs were characterized at one week post final vaccination. **(b)** To verify bone marrow replacement, unsupervised clustering of lung CD45⁺ cells was performed on flow cytometry data and relative expression of TLR2 was examined by FIt-SNE for each experimental group. **(c)** Mean (n=6) proportions of CD45⁺ cell populations in the lungs determined by flow cytometry, representative of two independent biological experiments, with **(d)** quantitation of populations of interest. Data are for individual mice from two independent biological experiments (n=4-6 each), means +/- SEM are shown. Statistics: p-values indicated, Kruskal-Wallis test, Dunn's multiple comparisons.

Figure 5

TLR2 expression by the hematopoietic lineage is required for optimal Spike-specific antibody and CD4⁺ T-cell responses in the lung following mucosal vaccination and boosting with Pam₂Cys Spike. *Tlr2*^{-/-} (KO) or wild type (WT) mice were lethally irradiated then received transfer of *Tlr2*^{-/-} or WT bone marrow (BM) cells i.v. Mice were rested for 12 weeks to allow hematopoietic reconstitution and replacement, then immunized with Pam₂Cys Spike i.n three times, two weeks apart. Immune responses were characterized at one week post final vaccination. Control mice were unvaccinated *Tlr2*^{-/-} (UNV). **(a)** Anti-spike IgG and IgA titres (log₁₀ scale) in serum and BALF determined by ELISA. **(b)** Neutralizing antibody (nAb) titres (log₁₀ scale) in serum and BALF of vaccinated mice were determined as the titre needed for 50%

inhibition of SARS-CoV-2 Spike-expressing lentivirus in HEK293-ACE2 cells. Limits of detection are indicated by the dotted lines. **(c)** Proportion of CD4⁺ T-cells and Bcl6⁺ CD4⁺ T-cells in mediastinal lymph nodes. Frequency of antigen-specific cytokine-producing CD4⁺ T-cells in the **(d)** lungs and **(e)** spleen, detected by intra-cellular staining and flow cytometry following recall with Spike protein in the presence of Brefeldin A. Statistics: p-values indicated, means +/- SEM are shown. (a-c) Data are for individual mice from two independent biological experiments (n=2-6 each), Kruskal-Wallis test, Dunn's multiple comparisons. (d-e) Representative of two independent biological experiments (n=4-6 each), two-way ANOVA, Tukey's multiple comparisons test.

Figure 6

Vaccination with Pam₂Cys Spike induces potent protection against SARS-CoV-2 challenge. K18-hACE2 mice (n=5) were immunized with Pam₂Cys alone, or Pam₂Cys Spike, s.c or i.n three times, two weeks apart. Three weeks post final vaccination mice were challenged with 10³ plaque forming units (PFU) of SARS-CoV-2 i.n and protective efficacy assessed. **(a)** Anti-Spike IgG and IgA titres (log₁₀ scale) in serum collected one week post final vaccination, determined by ELISA, and **(b)** neutralizing antibody (nAb) titres (log₁₀ scale) were determined as the titre needed for 50% inhibition of SARS-CoV-2 infection (ancestral, Beta or Delta variant) in HEK-ACE2-TMPRSS2 cells. **(c)** Mouse weight loss from days 0-7 post infection (p.i) with SARS-CoV-2. **(d)** Clinical score distribution, increasing category indicates severity, **(e)** total leukocyte and differential cell counts in the BALF and **(f)** lung viral load (PFU) at day 7 p.i. Limits of detection (LOD) indicated by the dotted lines. Data are for individual mice (n=5 each), means +/- SEM are shown. Statistics: p-values indicated. (a, b) Mann-Whitney test, (c) Two-way ANOVA with Tukey's multiple comparisons, (e, f) Kruskal-Wallis test, Dunn's multiple comparisons.

Figure 7

Pam₂Cys Spike vaccination protects mice from damaging leukocyte infiltration of the lung parenchyma during SARS-CoV-2 infection. **(a)** Quantitation of inflammatory cells in the lung parenchyma of vaccinated mice 7 days p.i. Data are for individual mice (n=5 each), means +/- SEM are shown. Statistics: p values indicated, Kruskal-Wallis test, Dunn's multiple comparisons. Representative lung histological sections from mice 7 days p.i with SARS-CoV-2, vaccinated with **(b)** Pam₂Cys s.c, **(c)** Pam₂Cys Spike s.c, **(d)** Pam₂Cys i.n, a representative for both unprotected and protected phenotypes are shown, and **(e)** Pam₂Cys Spike i.n. Scale bar = 50 mm.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [AshhurstASupplementaryfigures.pdf](#)